180 related articles for article (PubMed ID: 34965961)
21. Oncolytic viruses for potential osteosarcoma therapy.
Hingorani P; Sampson V; Lettieri C; Kolb EA
Adv Exp Med Biol; 2014; 804():259-83. PubMed ID: 24924179
[TBL] [Abstract][Full Text] [Related]
22. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune response in liver cancer.
Qiang L; Huili Z; Leilei Z; Xiaoyan W; Hui W; Biao H; Yigang W; Fang H; Yiqiang W
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18201-18213. PubMed ID: 38078962
[TBL] [Abstract][Full Text] [Related]
27. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
28. Antitumor effect of the Newcastle disease viral hemagglutinin-neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells.
Chen S; Zhang Q; Xu D; Li Y; Fan Y; Li W; Yin X; Zhang Y; Liu J; Li X; Sun L; Jin N
Anticancer Drugs; 2018 Mar; 29(3):197-207. PubMed ID: 29438228
[TBL] [Abstract][Full Text] [Related]
29. The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment.
Liu G; Hu Q; Peng S; Ning H; Mai J; Chen X; Tao M; Liu Q; Huang H; Jiang Y; Ding Y; Zhang X; Gu J; Xie Z
Cancer Lett; 2024 Jan; 581():216485. PubMed ID: 38008394
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.
Hu Z; Gerseny H; Zhang Z; Chen YJ; Berg A; Zhang Z; Stock S; Seth P
Mol Ther; 2011 Sep; 19(9):1609-18. PubMed ID: 21712815
[TBL] [Abstract][Full Text] [Related]
31. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
Hinterberger M; Giessel R; Fiore G; Graebnitz F; Bathke B; Wennier S; Chaplin P; Melero I; Suter M; Lauterbach H; Berraondo P; Hochrein H; Medina-Echeverz J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579736
[No Abstract] [Full Text] [Related]
33. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
34. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
35. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
Chen D; Huang L; Zhou H; Zhang Y
Front Immunol; 2021; 12():615089. PubMed ID: 33717103
[TBL] [Abstract][Full Text] [Related]
36. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
[TBL] [Abstract][Full Text] [Related]
37. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy.
Zhang L; Hedjran F; Larson C; Perez GL; Reid T
Cancer Gene Ther; 2015 Jan; 22(1):17-22. PubMed ID: 25525035
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy.
Huang H; Liu Y; Liao W; Cao Y; Liu Q; Guo Y; Lu Y; Xie Z
Nat Commun; 2019 Oct; 10(1):4801. PubMed ID: 31641136
[TBL] [Abstract][Full Text] [Related]
39. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
[TBL] [Abstract][Full Text] [Related]
40. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]